As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk

Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has blacklisted 37 medical-related companies, most of them Chinese, over concerns their skills and technology could be used to help the Chinese military Shares of companies that develop their own drugs are coming under more pressure than peers who license drugs from third-parties following the move   By Doug Young In these troubled times of U.S.-China tensions, sometimes being a copycat has…

Read More »

Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology

Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China  Key Takeaways: New China licensing deals and oncology focus come amid earnings slump, though profit declines eased in second half of 2020 Despite securing big name cornerstone investors, company’s shares have tumbled 40% since its October Hong Kong IPO, following its New York de-listing six years earlier By Richard Barbarossa Generic drug maker Simcere Pharmaceutical Group Ltd. (2906.HK) has sold off a money-losing unit making cell therapy drugs and is placing…

Read More »